Plus Therapeutics Secures $1.9 Million Advance Payment From CPRIT For Ongoing Projects

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced the receipt of an additional advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funder. This latest payment of $1.9 million is part of a previously awarded $17.6 million grant and represents the second non-dilutive funding received from CPRIT, following a $1.6 million payment announced in July 2025.

Andrew Sims, Chief Financial Officer of Plus Therapeutics, stated that the continued support from CPRIT provides a steady source of non-dilutive financing and is expected to be followed by another $1.9 million in funding over the next 12 months. He noted that this support complements the company’s existing grants from the National Institutes of Health and the Department of Defense, reflecting strong institutional backing for Plus Therapeutics’ clinical programs. The company is also actively seeking additional grant opportunities to further strengthen its capital position.

The funding will help advance the clinical development of REYOBIQ™ in the ReSPECT-LM dose optimization trial and support the continued development of the CNSide LM diagnostic test as a critical endpoint in pivotal trials. Plus Therapeutics said this financial support will accelerate its efforts to bring new targeted therapies and diagnostic tools to patients with CNS cancers.